ANI PHARMACEUTICALS INC (ANIP)

US00182C1036 - Common Stock

65.36  +0.41 (+0.63%)

After market: 62.35 -3.01 (-4.61%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
216.1M
3.65%		316.4M
46.41%		486.816M
53.86%		545.99M
12.16%
EBITDA
YoY % growth
19.35M
-52.03%		30.15M
55.81%		107.894M
257.86%		142.61M
32.18%
EBIT
YoY % growth
-27.9M
-548.84%		-29.5M
-5.73%		48.103M
263.06%		143.55M
198.42%
Operating Margin
-12.91%-9.32%9.88%26.29%
EPS
YoY % growth
3.26
-6.86%		1.41
-56.75%		4.72
234.75%		4.56
-3.40%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		1.00
-14.22%
Revenue
Q2Q % growth		127.77M
19.63%
EBITDA
Q2Q % growth		31.16M
EBIT
Q2Q % growth		32.688M
197.16%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 1.00
31.58%		0.870.1314.67%
Q3 2023
Q2Q % growth		 1.27
98.44%		0.860.4147.64%
Q2 2023
Q2Q % growth		 1.28
884.62%		0.690.5985.23%
Q1 2023
Q2Q % growth		 1.17
1,075.00%		0.360.81225.41%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 131.654M
39.76%		124.65M7.004M5.62%
Q3 2023
Q2Q % growth		 131.8M
57.28%		114.16M17.64M15.45%
Q2 2023
Q2Q % growth		 116.5M
57.65%		100.67M15.83M15.72%
Q1 2023
Q2Q % growth		 106.8M
65.58%		85.165M21.635M25.40%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0.41% -1.65% 4.85%
Revenue-0.53% 7.55% 0.72% 7.06%